Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class II and IV histone deacetylases (HDACs) are a subset of the zinc-dependent classical HDAC family, comprising isoforms HDAC4, 5, 7, and 9 (Class IIa), HDAC6 and 10 (Class IIb), and HDAC11 (Class IV) [1, 2]. Unlike Class I HDACs, which are primarily nuclear and ubiquitously expressed, Class II and IV enzymes exhibit tissue-specific expression and frequently shuttle between the nucleus and cytoplasm to deacetylate both histones and non-histone proteins, such as alpha-tubulin and Hsp90 [1, 3]. These enzymes play critical roles in diverse physiological processes, including muscle differentiation, cardiac development, and the regulation of immune cell signaling, notably through the HDAC11-mediated repression of the anti-inflammatory cytokine IL-10 [3, 4]. In pathological contexts, Class II and IV HDACs are often dysregulated, contributing to the progression of various cancers, neurodegenerative disorders like Parkinson's disease, and chronic inflammatory conditions [1, 5]. Therapeutic targeting of these classes involves both pan-HDAC inhibitors and isoform-selective agents, such as ricolinostat (HDAC6-selective), which aim to leverage their specific roles in disease while minimizing systemic toxicities like thrombocytopenia and cardiotoxicity [4, 6]. Sources: [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433950/ [2] https://www.uniprot.org/ [3] https://pubmed.ncbi.nlm.nih.gov/22449854/ [4] https://www.ncbi.nlm.nih.gov/books/NBK560560/ [5] https://www.nature.com/articles/nrd1975 [6] https://www.fda.gov/drugs/information-on-drugs/approved-drugs
Inhibition of the zinc-dependent catalytic site of Class II and IV histone deacetylases, preventing the removal of acetyl groups from lysine residues on histones and non-histone proteins. This leads to hyperacetylation, which alters chromatin structure to promote gene transcription (e.g., p21) or modulates the function of cytoplasmic proteins (e.g., tubulin, Hsp90), ultimately inducing cell cycle arrest, apoptosis, and anti-inflammatory effects [1, 4, 5].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class II and IV histone deacetylases (Class II/IV HDACs).